Heart & blood pressure · Birmingham area, AL
Heart and blood pressure studies in Birmingham area, AL
37 recruiting studies have a site in the Birmingham area. This page includes nearby cities such as Hoover, Homewood, Vestavia Hills, Bessemer.
37 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1
Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project
University of Alabama at Birmingham
- Location
- Birmingham, AL
- Eligibility basics
- Ages 14–89 · Women only
- Recruiting
Assessment of CCM in HF With Higher Ejection Fraction
Impulse Dynamics
- Location
- Birmingham, AL + 64 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Prevail Global Study
Medtronic Vascular
- Location
- Birmingham, AL + 53 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
AstraZeneca
- Location
- Birmingham, AL + 151 other US sites
- Eligibility basics
- Ages 40+
- Recruiting
Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)
Medtronic Cardiac Ablation Solutions
- Location
- Birmingham, AL + 20 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Renal Pelvic Denervation Pilot Trial
Verve Medical, Inc
- Location
- Birmingham, AL + 7 other US sites
- Eligibility basics
- Ages 21–80
- RecruitingPhase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Alnylam Pharmaceuticals
- Location
- Birmingham, AL + 213 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Cytokinetics
- Location
- Alexander City, AL + 80 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 2
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
Edgewise Therapeutics, Inc.
- Location
- Birmingham, AL + 3 other US sites
- Eligibility basics
- Ages 30–84
- Recruiting
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Tempus AI
- Location
- Birmingham, AL + 39 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company
- Location
- Anniston, AL + 68 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Zenith® Fenestrated+ Clinical Study
Cook Research Incorporated
- Location
- Birmingham, AL + 29 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
Novo Nordisk A/S
- Location
- Birmingham, AL + 16 other US sites
- Eligibility basics
- Ages 40–84
- RecruitingPhase 2/Phase 3
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Kardigan, Inc.
- Location
- Birmingham, AL + 26 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
Retension Pharmaceuticals. Inc.
- Location
- Alexander City, AL + 31 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Kardigan, Inc.
- Location
- Birmingham, AL + 2 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation
Biosense Webster, Inc.
- Location
- Birmingham, AL + 10 other US sites
- Eligibility basics
- Ages 18–80
- Recruiting
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
SoniVie Inc.
- Location
- Birmingham, AL + 33 other US sites
- Eligibility basics
- Ages 22–75
- RecruitingPhase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Amgen
- Location
- Birmingham, AL + 117 other US sites
- Eligibility basics
- Ages 18–99
- Recruiting
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Medtronic Cardiovascular
- Location
- Birmingham, AL + 68 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.
XyloCor Therapeutics, Inc.
- Location
- Birmingham, AL + 12 other US sites
- Eligibility basics
- Ages 18–85
- Recruiting
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
BrioHealth Solutions, Inc.
- Location
- Birmingham, AL + 46 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 1/Phase 2
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
Alexion Pharmaceuticals, Inc.
- Location
- Birmingham, AL + 6 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
AstraZeneca
- Location
- Athens, AL + 206 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Many require a diagnosis or specific lab values such as LDL cholesterol or blood pressure readings, and exclude recent heart events.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.